Hematopoietic stem cell transplantation (HSCT) is a widely accepted treatment for malignant and nonmalignant disorders. Recent advances in transplantation techniques have increased the rate of long-term survival. However, kidney complications after HSCT are an important challenge.1,2 Recent studies have shown that the prevalence of chronic kidney disease (CKD) is approximately 20% in HSCT recipients.2–6 The existence of CKD can affect outcomes and reduce survival. In particular, among patients who developed end-stage renal disease (ESRD) and required dialysis, mortality rates were very high.
No takes yet. Share an insight, caveat, or question.
Mii et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: